Achieve Life Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Tables)

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2016

Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis

The following table presents information about our assets and liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value (in thousands):

June 30, 2016	Level 1		Level 2		Level 3		Total
Assets
Cash	$	2,401	$	—	$	—	$	2,401
Money market securities		8,180		—		—		8,180
Restricted cash (Note 7)		272		—		—		272
Corporate bonds and commercial paper		—		29,147		—		29,147
Total assets	$	10,853	$	29,147	$	—	$	40,000
Liabilities
Warrants	$	—	$	—	$	971	$	971

Summary of Changes in Fair Value of Level 3 Financial Liabilities

The following table presents the changes in fair value of our total Level 3 financial liabilities for the six months ended June 30, 2016. During the six months ended June 30, 2016, we did not issue any common stock warrants that were classified as liabilities (in thousands):

	Liability at				Unrealized			Liability at
	December 31,		Issuance of		Gain on			June 30,
	2015		Warrants		warrants			2016
Warrant liability	$	1,105	$	—	$	(134	)	$	971

Summary of Cash, Cash Equivalents and Short-Term Investments

Cash, cash equivalents and short-term investments consist of the following (in thousands):

			Gross		Gross
	Amortized		Unrealized		Unrealized			Estimated
June 30, 2016	Cost		Gains		Losses			Fair Value
Cash	$	2,401	$	—	$	—		$	2,401
Money market securities		8,180		—		—			8,180
Total cash and cash equivalents	$	10,581	$	—	$	—		$	10,581
Money market securities (restricted cash)		272		—		—			272
Total restricted cash	$	272	$	—	$	—		$	272
Corporate bonds and commercial paper		29,138		10		(1	)		29,147
Total short-term investments	$	29,138	$	10	$	(1	)	$	29,147